Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8 + T cell cytotoxicity over BEMPEG+RT.

Annah S RoligDaniel C RoseGrace Helen McGeeWerner RubasSaul KivimäeWilliam L Redmond

Published in: Journal for immunotherapy of cancer (2022)

T cells compared with BEMPEG+RT, suggesting that intratumoral TLR stimulation provides superior antigen presentation and costimulatory activity compared with RT. A clinical trial of BEMPEG+NKTR-262 for patients with metastatic solid tumors is in progress (NCT03435640).

Keyphrases

clinical trial
toll like receptor
inflammatory response
immune response
nuclear factor
open label
study protocol
double blind